Search


Current filters:

Clear current filters  or Add more filters

View Option



Results 1-10 of 37 (Search time: 0.004 seconds).

  Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome (Journal article)

  Increased plasma visfatin levels in subjects with the metabolic syndrome (Journal article)

  Small dense LDL cholesterol and apolipoproteins C-II and C-III in non-diabetic obese subjects with metabolic syndrome (Journal article)

  The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia (Journal article)

  Plasma PAF-acetylhydrolase(Lp-PLA(2)) activity as a marker of small-dense LDL in subjects at median cardiovascular risk (Journal article)

  The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome (Journal article)

  The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia (Journal article)

  Effects of Fenofibrate and Orlistat, Alone or in Combination, on Plasma Visfatin Levels in Subjects with Metabolic Syndrome (Journal article)

  Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia (Journal article)

  Effects of orlistat and fenofibrate combination on LDL phenotype in overweight and obese patients with metabolic syndrome. The fenorli study (Journal article)